BACKGROUND: Measuring vaccine effectiveness (VE) relies on the use of observational study designs. However, achieving robust estimates of direct and indirect VE is frequently compromised by bias, particularly when using syndromic diagnoses of low-specificity. METHODS: In order to mitigate confounding between the measured outcome and vaccine uptake, we developed a method to balance comparator populations using individual-level propensity scoring derived from the vaccine-exposed population, and applied it to the unexposed comparator population. Indirect VE was estimated by comparing the unvaccinated vaccine-exposed group with a propensity score-simulated unvaccinated, unexposed group. Direct VE was derived by removing indirect VE from the ove...
BackgroundRotavirus was the leading cause of acute gastroenteritis (AGE) in infants and young childr...
Reports of unexplained discrepancies in the efficacy of vaccines, as estimated from randomised contr...
INTRODUCTION: Rotavirus vaccine efficacy ranges from >90% in high socio-economic settings (SES) to 5...
Background:Measuring vaccine effectiveness (VE) relies on the use of observational study designs.How...
Background: Rotavirus is the leading cause of diarrheal diseases worldwide and is responsible for su...
Background: Motivated by the unexplained variation in the performance of some vaccines across differ...
BACKGROUND:Studies of vaccine effectiveness (VE) rely on accurate identification of vaccination and ...
© 2018 Elsevier Ltd Background: Motivated by the unexplained variation in the performance of some va...
Background: Motivated by the unexplained variation in the performance of some vaccines across differ...
Background: Published economic assessments of rotavirus vaccination typically use modelling, mainly ...
Background: Published economic assessments of rotavirus vaccination typically use modelling, mainly ...
Abstract Background The direct effectiveness of infant rotavirus vaccination implemented in 2006 in ...
BACKGROUND: Published economic assessments of rotavirus vaccination typically use modelling, mainly ...
Published economic assessments of rotavirus vaccination typically use modelling, mainly static Marko...
Published economic assessments of rotavirus vaccination typically use modelling, mainly static Marko...
BackgroundRotavirus was the leading cause of acute gastroenteritis (AGE) in infants and young childr...
Reports of unexplained discrepancies in the efficacy of vaccines, as estimated from randomised contr...
INTRODUCTION: Rotavirus vaccine efficacy ranges from >90% in high socio-economic settings (SES) to 5...
Background:Measuring vaccine effectiveness (VE) relies on the use of observational study designs.How...
Background: Rotavirus is the leading cause of diarrheal diseases worldwide and is responsible for su...
Background: Motivated by the unexplained variation in the performance of some vaccines across differ...
BACKGROUND:Studies of vaccine effectiveness (VE) rely on accurate identification of vaccination and ...
© 2018 Elsevier Ltd Background: Motivated by the unexplained variation in the performance of some va...
Background: Motivated by the unexplained variation in the performance of some vaccines across differ...
Background: Published economic assessments of rotavirus vaccination typically use modelling, mainly ...
Background: Published economic assessments of rotavirus vaccination typically use modelling, mainly ...
Abstract Background The direct effectiveness of infant rotavirus vaccination implemented in 2006 in ...
BACKGROUND: Published economic assessments of rotavirus vaccination typically use modelling, mainly ...
Published economic assessments of rotavirus vaccination typically use modelling, mainly static Marko...
Published economic assessments of rotavirus vaccination typically use modelling, mainly static Marko...
BackgroundRotavirus was the leading cause of acute gastroenteritis (AGE) in infants and young childr...
Reports of unexplained discrepancies in the efficacy of vaccines, as estimated from randomised contr...
INTRODUCTION: Rotavirus vaccine efficacy ranges from >90% in high socio-economic settings (SES) to 5...